-
Un’indagine presso 2 centri oncologici del Regno Unito indica che docetaxel è associato a effetti peggiori rispetto a paclitaxel.
-
Up to 10% of patients with breast cancer experience severe pCIA.
-
Post hoc analyses suggest superior long-term efficacy of ixekizumab.

A recent study suggests the risk of meningioma remains increased at least one year after cessation of treatment.